VEPPANU
vepdegestrant · ARV-471 Small Molecule Target: estrogen receptor, ER, ESR1
ARVINAS, INC.
Most recent annual filing: 2026-02-24
Pipeline (15 active programs)
ARV-102
Small Molecule Target: LRRK2
ARV-806
Small Molecule Target: KRAS G12D
ARV-393
Small Molecule Target: BCL6
ARV-027
ARV-6723
Small Molecule Target: HPK1
- Undisclosed indication
- Undisclosed indication
luxdegalutamide
ARV-766 Small Molecule Target: androgen receptor, AR
bavdegalutamide
ARV-110 Small Molecule Target: androgen receptor
- Undisclosed indication
pan-KRAS degrader
Small Molecule Target: KRAS
- Undisclosed indication
Technology platforms
PROTAC Discovery Engine
Integrated suite of tools and expertise for discovery and optimization of PROTAC targeted protein degraders, including E3KnowledgeBase, ANGLE linker evolution, LEAP library format, PROTACify ML modeling, proteomics capabilities, and PIVOT PK/PD tool. Focus areas: oncology and neurology, including historically undruggable intracellular targets such as transcription factors, scaffolding proteins, and oncoproteins.
PROTAC
PROteolysis TArgeting Chimera protein degrader platform — harnesses the body's natural protein disposal system to selectively degrade disease-causing intracellular proteins, including historically undruggable targets, across oncology and neurology indications.
Discontinued (1)
- bavdegalutamide — Metastatic Castration-Resistant Prostate Cancer · deprioritized in favor of luxdegalutamide; clinical trials completed Q2 2025
Biotech Distilled coverage (3)
- 2026-05-12 UPDATE: Arvinas (ARVN) - The Partner Lands. The Tape Yawns. 🔒 Paid
- 2026-05-02 UPDATE: Arvinas (ARVN) - The First PROTAC Crosses the Finish Line 🔒 Paid
- 2026-04-10 Arvinas (ARVN) - Scientific Deep Dive for Vepdegestrant, Luxdegalutamide, and Pipeline Products 🔒 Paid
Articles open on Substack. Some deep dives are subscriber-only.